Treatment of chronic hepatitis C in haemophiliac patients
Abstract number: 1135_256
Husa P., Roznovsky L., Smejkal P., Husova L., Penka M.
Chronic hepatitis C infection is very common among haemophiliacs in the developed World.
Retrospective evaluation of the treatment results in haemophiliacs with chronic hepatitis C, all infected with genotype 1b. Twelve patients were treated with interferon-alfa monotherapy, 21 patients with interferon-alfa and ribavirin, and 3 patients with pegylated interferon and ribavirin, all for 48 weeks.
Sustained virologic response (defined as an undetectable serum HCV RNA level 24 weeks after treatment was completed) was not achieved in any of 12 patients treated with interferon-alfa alone. Combination therapy with interferon-alfa and ribavirin was associated with better results: 4/10 (40%) patients still untreated with interferon-alfa, 2/4 (50%) relapsers, and 2/7 (29%) non-responders to previous interferon-alfa monotherapy achieved sustained virologic responses. Combination therapy with pegylated interferon and ribavirin has been used in 3 patients. Sustained response was achieved in one patient who had relapsed after treatment with interferon-alfa and ribavirin and in 1 of 2 non-responders to this combination therapy. There were no serious adverse events and it was not necessary to reduce dosages or even cease therapy prematurely.
The efficacy and tolerability of antiviral treatment in haemophiliacs did not differ from other patients with chronic hepatitis C.
|Session name:||XXIst ISTH Congress|
|Back to top|